Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.079.921 |
Chemical and physical data | |
Formula | C7H7ClN6O2 |
Molar mass | 242.62 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]